ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
New Testosterone Nasal Spray Offers Patients an Alternative
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 158248" data-attributes="member: 13851"><p>No it is an aqueous solution (spray) as oppose to NATESTO® which is a gel.</p><p></p><p></p><p><strong><span style="color: rgb(44, 130, 201)">UT Austin psychology professor Robert Josephs </span><span style="color: rgb(184, 49, 47)">and </span><span style="color: rgb(44, 130, 201)">MedCara Pharmaceuticals pharmacist Craig Herman </span><span style="color: rgb(184, 49, 47)">developed their nasal spray</span> in response to a long-standing research question about why women are twice as likely as men to develop anxiety disorders. </strong></p><p></p><p></p><p></p><p><a href="https://clinicaltrials.gov/ct2/show/NCT02361190" target="_blank">Effects of Fast Acting Testosterone Nasal Spray on Anxiety - Full Text View - ClinicalTrials.gov</a></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">O12.</span> Intranasal Testosterone Reduces Stress-Evoked Anxiety in Women </strong></p><p></p><p><strong>Ellie Shuo Jin and <span style="color: rgb(44, 130, 201)">Robert Alan Josephs</span></strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>The University of Texas at Austin </strong></span></p><p></p><p></p><p></p><p></p><p></p><p><strong>Background:</strong> Can a single-dose of a testosterone-containing nasal spray reduce anxiety? Although both exogenous and endogenous testosterone have been associated with reductions in implicitly measured fear responses, it remains unknown whether exogenous testosterone can reduce the explicit, subjective experience of anxiety in humans</p><p></p><p></p><p><strong>Methods:</strong> In the present study, participants (N ¼ 104, 48.1% female) were randomly assigned to receive either testosterone or placebo via intranasal spray before taking part in an acute psychosocial stressor. Participants used visual analogue scales to rate their subjective anxiety before, during, and after the stressor.</p><p></p><p></p><p><strong>Results:</strong> Results revealed a statistically significant drug by sex interaction, in which women as expected experienced significantly higher levels of subjective anxiety in the placebo condition compared to men; a sex difference that was eliminated in the drug condition. <span style="color: rgb(0, 0, 0)"><strong>Further, women randomized to the testosterone condition</strong></span> <span style="color: rgb(184, 49, 47)"><strong>experienced significantly lower levels of anxiety during recovery from the acute stressor relatively to women in the placebo condition.</strong></span></p><p></p><p></p><p><strong>Conclusions:</strong> <span style="color: rgb(184, 49, 47)"><strong>Taken together, these results have important implications for the etiology of anxiety and treatment.</strong></span></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>The <strong><span style="color: rgb(184, 49, 47)">nasal spray </span>(United States <span style="color: rgb(184, 49, 47)">Patent No. 10,258,63,</span> <span style="color: rgb(184, 49, 47)">issued on April 16, 2019</span>) </strong>has been <a href="http://www.aceruspharma.com/English/news/press-release-details/2019/Acerus-Signs-License-Agreement-to-Nasal-Technology-with-University-of-Texas-at-Austin/default.aspx" target="_blank">licensed to Acerus Pharmaceuticals Corporation</a>, which has the flexibility under the current agreement to use the technology in whatever medical field it deems most appropriate.</p></blockquote><p></p>
[QUOTE="madman, post: 158248, member: 13851"] No it is an aqueous solution (spray) as oppose to NATESTO® which is a gel. [B][COLOR=rgb(44, 130, 201)]UT Austin psychology professor Robert Josephs [/COLOR][COLOR=rgb(184, 49, 47)]and [/COLOR][COLOR=rgb(44, 130, 201)]MedCara Pharmaceuticals pharmacist Craig Herman [/COLOR][COLOR=rgb(184, 49, 47)]developed their nasal spray[/COLOR] in response to a long-standing research question about why women are twice as likely as men to develop anxiety disorders. [/B] [URL='https://clinicaltrials.gov/ct2/show/NCT02361190']Effects of Fast Acting Testosterone Nasal Spray on Anxiety - Full Text View - ClinicalTrials.gov[/URL] [B][COLOR=rgb(184, 49, 47)]O12.[/COLOR] Intranasal Testosterone Reduces Stress-Evoked Anxiety in Women [/B] [B]Ellie Shuo Jin and [COLOR=rgb(44, 130, 201)]Robert Alan Josephs[/COLOR][/B] [COLOR=rgb(184, 49, 47)][B]The University of Texas at Austin [/B][/COLOR] [B]Background:[/B] Can a single-dose of a testosterone-containing nasal spray reduce anxiety? Although both exogenous and endogenous testosterone have been associated with reductions in implicitly measured fear responses, it remains unknown whether exogenous testosterone can reduce the explicit, subjective experience of anxiety in humans [B]Methods:[/B] In the present study, participants (N ¼ 104, 48.1% female) were randomly assigned to receive either testosterone or placebo via intranasal spray before taking part in an acute psychosocial stressor. Participants used visual analogue scales to rate their subjective anxiety before, during, and after the stressor. [B]Results:[/B] Results revealed a statistically significant drug by sex interaction, in which women as expected experienced significantly higher levels of subjective anxiety in the placebo condition compared to men; a sex difference that was eliminated in the drug condition. [COLOR=rgb(0, 0, 0)][B]Further, women randomized to the testosterone condition[/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]experienced significantly lower levels of anxiety during recovery from the acute stressor relatively to women in the placebo condition.[/B][/COLOR] [B]Conclusions:[/B] [COLOR=rgb(184, 49, 47)][B]Taken together, these results have important implications for the etiology of anxiety and treatment.[/B][/COLOR] The [B][COLOR=rgb(184, 49, 47)]nasal spray [/COLOR](United States [COLOR=rgb(184, 49, 47)]Patent No. 10,258,63,[/COLOR] [COLOR=rgb(184, 49, 47)]issued on April 16, 2019[/COLOR]) [/B]has been [URL='http://www.aceruspharma.com/English/news/press-release-details/2019/Acerus-Signs-License-Agreement-to-Nasal-Technology-with-University-of-Texas-at-Austin/default.aspx']licensed to Acerus Pharmaceuticals Corporation[/URL], which has the flexibility under the current agreement to use the technology in whatever medical field it deems most appropriate. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
New Testosterone Nasal Spray Offers Patients an Alternative
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top